Mannkind Corp (MNKD): who owns it and who trades it
As of Nov 16, 2026, MNKD insiders reported 13 open-market sales worth $3.2M and 1 purchase worth $259K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Michael Castagna (CEO), with $1.2M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Mannkind
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MNKD
258 funds and institutions reported MNKD shares worth $786M at the end of Q2 2026, about 60% of the company. The largest holder is BlackRock, Inc. with 10.4%.
Funds and institutions (13F) 60%Everyone else 40%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 32.13M | 10.40% | $137M | +12% |
| Rubric Capital Management LP | 18.00M | 5.83% | $76.7M | +397% |
| State Street Corp | 16.17M | 5.24% | $68.9M | -13% |
| Vanguard Capital Management LLC | 13.17M | 4.26% | $56.1M | +2% |
| Geode Capital Management, LLC | 7.95M | 2.57% | $33.9M | +6% |
| Wellington Management Group LLP | 7.84M | 2.54% | $33.4M | +139% |
| Frazier Life Sciences Management, L.P. | 6.60M | 2.14% | $28.1M | +12% |
| Deep Track Capital, LP | 6.00M | 1.94% | $25.6M | – |
| 180 Wealth Advisors, LLC | 4.96M | 1.61% | $21.1M | +16% |
| FMR LLC (Fidelity) | 4.10M | 1.33% | $17.5M | +18% |
| TSP Capital Management Group, LLC | 3.97M | 1.29% | $16.9M | – |
| AQR Capital Management LLC | 3.81M | 1.23% | $16.2M | +741% |
| Morgan Stanley | 3.47M | 1.12% | $14.8M | -40% |
| Braidwell LP | 3.46M | 1.12% | $14.7M | – |
| Vanguard Portfolio Management LLC | 3.00M | 0.97% | $12.8M | -5% |
| Northern Trust Corp | 2.89M | 0.93% | $12.3M | +8% |
| UBS Group AG | 2.89M | 0.93% | $12.3M | -65% |
| Two Sigma Investments, LP | 2.69M | 0.87% | $11.5M | -7% |
| Charles Schwab Investment Management Inc | 2.60M | 0.84% | $11.1M | +2% |
| Sixth Street Partners Management Company, L.P. | 2.60M | 0.84% | $11.1M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MNKD insiders reported $259K of open-market purchases and $3.2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Steven B. Binder | Director | Sale | 39,051 | $3.29 | $128K | Form 4 |
| Sep 10, 2026 | Steven B. Binder | Director | Sale | 33,558 | $3.81 | $128K | Form 4 |
| Aug 7, 2026 | Steven B. Binder | Director | Sale | 39,051 | $4.06 | $159K | Form 4 |
| Jul 17, 2026 | David Thomson | Vice president | Sale | 24,109 | $4.05 | $97.6K | Form 4 |
| Jul 17, 2026 | Steven B. Binder | Director | Sale | 52,485 | $4.06 | $213K | Form 4 |
| May 12, 2026 | Steven B. Binder | Director | Sale | 16,940 | $3.29 | $55.7K | Form 4 |
| May 12, 2026 | David Thomson | Vice president | Sale | 3,033 | $3.29 | $10K | Form 4 |
| Mar 10, 2026 | Michael Castagna | CEO | Purchase | 100,000 | $2.59 | $259K | Form 4 |
| Jan 8, 2026 | Stuart A Tross | Chief People & Workpl Of | Sale | 47,006 | $6.33 | $298K | Form 4 |
| Dec 17, 2025 | Michael Castagna | CEO | Sale | 65,804 | $6.01 | $395K | Form 4 |
| Dec 16, 2025 | Michael Castagna | CEO | Sale | 21,310 | $6.00 | $128K | Form 4 |
| Dec 12, 2025 | Michael Castagna | CEO | Sale | 20,806 | $6.00 | $125K | Form 4 |
| Dec 2, 2025 | Michael Castagna | CEO | Sale | 107,920 | $5.57 | $601K | Form 4 |
| Dec 2, 2025 | David Thomson | Vice president | Sale | 147,780 | $5.57 | $823K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer, Director | $259K | $1.2M | Mar 10, 2026 |
| David Thomson | EVP Genl Counsel & Secretary | – | $931K | Jul 17, 2026 |
| Steven B. Binder | Director | – | $684K | Sep 25, 2026 |
| Stuart A Tross | Chief People & Workpl Officer | – | $298K | Jan 8, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MNKD short interest
Moderate short interest. 8.2% of MNKD shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 11%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 26.22M MNKD shares were sold short, 8.2% of the shares outstanding, up 2.9% from the report before. At the average daily volume of 2.54M shares, buying them all back would take about 10.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 26.22M | 8.15% | +3% | 2.54M | 10.3 |
| Oct 15, 2026 | 25.48M | 7.92% | -3% | 5.04M | 5.1 |
| Sep 30, 2026 | 26.16M | 8.14% | -11% | 5.90M | 4.4 |
| Sep 15, 2026 | 29.40M | 9.14% | +11% | 3.24M | 9.1 |
| Aug 31, 2026 | 26.55M | 8.26% | -7% | 3.13M | 8.5 |
| Aug 14, 2026 | 28.58M | 8.89% | +2% | 5.10M | 5.6 |
| Jul 31, 2026 | 27.90M | 8.68% | -1% | 4.47M | 6.2 |
| Jul 15, 2026 | 28.19M | 9.12% | +8% | 4.82M | 5.8 |
| Jun 30, 2026 | 26.19M | 8.48% | -16% | 5.94M | 4.4 |
| Jun 15, 2026 | 31.25M | 10.12% | +3% | 4.58M | 6.8 |
| May 29, 2026 | 30.33M | 9.82% | +3% | 6.12M | 5.0 |
| May 15, 2026 | 29.39M | 9.51% | -1% | 8.78M | 3.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Mannkind company events
Mannkind filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 21, 2026AnnouncementMannKind Corporation filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the Securities and Exchange Commission. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 24, 2026AnnouncementThe U.S. Food and Drug Administration approved Furoscix ReadyFlow ™ (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease. Filing
- Jun 2, 2026AnnouncementWe announced that the U.S. Food and Drug Administration (FDA) approved Afrezza®(insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes. Filing
- May 28, 2026AnnouncementRegulatory Update In connection with the approval of the Biologics License Application for Afrezza in June 2014, the U.S. Food and Drug Administration required us to conduct a five-year, randomized, controlled trial in 8,000-10,000 patients with type 2 diabetes to assess the risk of pulmonary… Filing
- May 22, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Mannkind financials
Famous investors that hold MNKD
3 of the 50 well-known investors we track reported holding MNKD in their latest 13F filing. The largest position is Steve Cohen's, worth $4.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.22M | $4.8M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 920,001 | $3.6M | 0.0% | +113% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 397,240 | $1.5M | 0.0% | -56% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MNKD in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.7% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.7% |
Questions about Mannkind Corp (MNKD) stock
Who owns the most MNKD stock?
The largest reported owner of Mannkind Corp (MNKD) is BlackRock, Inc., with 10.4% of the company. In total, 258 funds and institutions reported holding MNKD at the end of Q2 2026, together about 60% of the shares. See the largest owners.
Are MNKD insiders buying or selling?
In the last 12 months, MNKD insiders reported 1 open-market purchase worth $259K and 13 sales worth $3.2M. The latest trade was on Sep 25, 2026. See every trade.
What is the short interest in MNKD?
As of Oct 30, 2026, 26.22M MNKD shares were sold short, 8.2% of the shares outstanding, up 2.9% from the report before. At the average daily volume of 2.54M shares, buying them all back would take about 10.3 trading days (days to cover). See the history.
Which famous investors hold MNKD?
3 of the 50 well-known investors we track reported MNKD in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $4.8M. See all holders.
Executive pay
Mannkind's chief executive was paid a total of $9.3M for the year ended Dec 31, 2025, down 2% from $9.5M the year before. In the last 12 months, Mannkind's executives and directors bought $259K of stock on the open market and sold $3.2M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.